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Abstract
Background: Gemcitabine, alone or in combination with other agents, has become an important part of the standard of care for treatment of both resectable and unresectable/advanced pancreatic adenocarcinoma. Gemcitabine
is generally considered to have a favorable toxicity proﬁle, with myelosuppression and hepatotoxicity as the most
common adverse effects. There are just two prior published case reports of gemcitabine-associated digital toxicity
in the treatment of pancreatic adenocarcinoma, and few case reports when considering all solid tumors.
Presentation: A 70-year-old female developed hand numbness and tingling while receiving nab-paclitaxel plus
gemcitabine for metastatic pancreatic adenocarcinoma. There was initial concern for Raynaud’s or nab-paclitaxelassociated neuropathy, thus nab-paclitaxel was discontinued. However, her symptoms progressed to severe pain
and her digits became dusky. An extensive evaluation revealed no alternative etiology except gemcitabineassociated digital ischemia (DI). The patient was treated with discontinuation of gemcitabine, and starting nitrates,
opiates, calcium-channel blockers, and enoxaparin but eventually progressed to dry gangrene.
Conclusion: Here we report a case of gemcitabine-associated DI, along with a review of the literature. Although
a rare complication, DI must be recognized and treated promptly to reduce the likelihood of serious and permanent morbidity.
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presented to clinic with numbness and tingling in her
bilateral hands. Owing to initial concern for nabpaclitaxel-associated neurotoxicity, nab-paclitaxel was
discontinued while the patient was continued on gemcitabine (cumulative dose 4160 mg/m2). At 2-week
follow-up, the patient reported progressive tenderness,
coolness, and purple discoloration of her bilateral index
ﬁngers that was initially relieved with warm water immersion. Gemcitabine was promptly discontinued and
the patient was admitted for further management. The
patient had previously received FOLFOX and then
FOLFIRI. She had a history of soleal deep vein thrombosis but no history of rheumatological, connective tissue or peripheral vascular disease. She was a 15-pack/

Introduction
Gemcitabine as a single agent or in combination therapy is a mainstay treatment for pancreatic adenocarcinoma.1,2 Gemcitabine is generally well tolerated, with a
favorable toxicity proﬁle.1 There are case reports of
gemcitabine-associated digital ischemia (DI), but there
are only two prior case reports in the treatment of pancreatic adenocarcinoma.3–5 Here we present a case of
gemcitabine-associated DI in a patient with pancreatic
adenocarcinoma, along with a literature review.
Case Report
A 70-year-old female with metastatic pancreatic adenocarcinoma receiving gemcitabine and nab-paclitaxel
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FIG. 1. Images of ﬁngers/hands. Red arrows,
bilateral index ﬁngers demonstrating cyanosis,
digital ischemia, and necrosis. Box, remaining
digits demonstrating cyanosis and distal
erythema.

50

year smoker but quit 2 years previously. Her medications included diltiazem, pravastatin, and aspirin.
Upon admission, the patient’s vital signs were within
normal limits. Examination revealed bilateral necrotic index ﬁngers (Fig. 1). Basic laboratories revealed leukocytosis, mild anemia, and hypoalbuminemia. The
prothrombin time/international normalized ratio, partial
thromboplastin time, lupus anticoagulant, anticardiolipin antibody, cryoglobulin S, C3/C4, and extractable
nuclear antigen testing were unremarkable. Antinuclear
antibody was positive with 1:320 titer and speckled pattern. Echocardiogram showed no evidence of intracardiac thrombi. CT angiography revealed no evidence of
systemic emboli. Arterial Doppler studies showed immeasurable digit/arm indices (Fig. 2). Given the negative evaluation for competing etiologies, gemcitabineassociated DI was diagnosed. The patient was managed
with gemcitabine discontinuation, along with initiation
of calcium-channel blockade, nitrates, and opiates. Therapeutic enoxaparin was also initiated, but was subsequently
discontinued because of gastrointestinal bleed. Despite
treatment, the patient’s symptoms progressed to dry gangrene of the bilateral index ﬁngers.

FIG. 2. Digit-arm indices. Digit-arm arterial Doppler tracings and indices demonstrating loss of arterial ﬂow to
the bilateral index ﬁngers (second digit).
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Table 1. Reported Cases of Gemcitabine-Associated Digital Ischemia

Right fourth digit,
and left ﬁrst,
second digits

Digits of both
hands

Left second, third,
and fourth digits

Right second, fourth,
ﬁfth ﬁngers and
left third ﬁnger

Left fourth, fifth
digits and right
third, fourth
digits
Second, third digits
of bilateral hands

Multiple fingers
and toes

Two digits of a
right foot

All digits of
both hands

Bilateral second
digits

Affected area

Stopped gemcitabine, started vasodilator
agents, low-molecular weight
heparin and aspirin
Stopped gemcitabine, started
intermittent corticosteroids

Started aspirin, calcium channel blocker,
low-molecular weight heparin

Started calcium channel blocker,
prednisolone, cephalexin, gabapentin,
and two stellate ganglion blocks

Stopped gemcitabine, started
calcium-channel blockade, nitrates,
opiates, and enoxaparin
Stopped gemcitabine, started prolonged
infusion of a prostacycline analogue,
NSAIDs, and opioids
Stopped gemcitabine, started prolonged
infusion of a prostacycline analogue,
percutaneous luminal angioplasty
of right superﬁcial femoralis artery
Stopped gemcitabine, started
prostaglandins, vasodilators, antiplatelet
drugs, antithrombin, bosentan hydrate,
and systemic nerve block
Stopped gemcitabine, started bilateral
brachial plexus blockade, intravenous
prostacyclin analogue, fractionated
heparin, oral corticosteroids, and aspirin
Stopped gemcitabine, started intravenous
prostaglandin-E2 analogue

Treatment for digital ischemia

Fixed gangrene

Partial clinical
improvement, NOS

Partial clinical
improvement NOS

Fixed gangrene requiring
amputation of affected
digits

Complete resolution

Partial clinical improvement,
but with residual ﬁxed
gangrene

Fixed gangrene not requiring
amputation of affected digits

Progressed to dry gangrene
of the bilateral second
digits
Symptoms resolved in all
digits except one, which
required amputation
Complete resolution

Outcome
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Discussion
Gemcitabine has been associated with thrombotic vascular complications affecting various organ systems.3
However, DI is a rare adverse effect of gemcitabine
likely caused by drug-related microvascular endothelial
damage and a relative hypercoagulable state,3 with only
case reports to aid clinicians in identifying risk factors,
recognizing signs/symptoms, and guiding management
decisions. A PubMed search using ‘‘digital ischemia/
necrosis’’ and ‘‘gemcitabine,’’ selecting English language
articles and also using relevant cases from those articles’
references revealed nine cases of gemcitabine-associated
DI (Table 1), with only two cases occurring in pancreatic adenocarcinoma. Risk factors included tobacco
use, diabetes, peripheral vascular disease, systemic
sclerosis, combination chemotherapy, and cumulative gemcitabine dose >10,000 mg/m.2,4–11 Two cases
reported favorable outcomes. Kuhar et al. reported
using infusion of a prostacycline analogue, NSAIDs,
and opioids.4 Vénat-Bouvet et al. reported intravenous prostaglandin-E2 analogue alone.12 In each
case, gemcitabine was withdrawn.
In this case, there was no underlying disease. Prior
smoking was the only risk factor. The cumulative
gemcitabine dose of 4160 mg/m2 was lower than previous reports. Given the lack of risk factors and initial
suspicion for competing etiologies, gemcitabine was
not immediately discontinued. Despite eventual discontinuation of gemcitabine and initiation of vasodilator therapy, the patient suffered irreversible digital
necrosis. Therefore, based on variability in risk factors
and cumulative dose exposure, clinicians should
maintain a high degree of suspicion for gemcitabineassociated DI.
Conclusion
DI is a rare side effect of gemcitabine, which may be attributable to endothelial damage and a hypercoagulable
state. There is variability in risk factors, presenting
signs/symptoms, and treatment response, creating a diagnostic and treatment dilemma for clinicians. Withdrawing gemcitabine and initiation of prostaglandins
and/or alternative vasodilators may be an effective
treatment modality.
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Abbreviations Used
CT ¼ computed tomography
DI ¼ digital ischemia
NSAIDs ¼ non-steroidal anti-inﬂammatory drugs
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